Newsletter Signup - Under Article / In Page"*" indicates required fields Kinases regulate nearly every aspect of cellular function – they act as molecular switches, controlling cell signaling pathways involved in growth, metabolism, immune responses, and apoptosis. Their dysregulation has been implicated in numerous diseases, particularly cancer. This is where kinase inhibitors come into play.Kinases have become one of the most extensively targeted enzymes in drug development. While traditional chemotherapies broadly attack dividing cells, kinase inhibitors are more specific. They have been very successful in oncology with therapies such as imatinib (Gleevec), now established as an important treatment of chronic myeloid leukemia (CML). But their contributions go beyond oncology as they are investigated for autoimmune diseases, fibrosis, and even neurodegenerative conditions.Given the sheer diversity of kinases and their inhibitors, this article will break down the major categories, highlight breakthrough therapies, and spotlight the exciting innovations shaping the next wave of targeted treatments.Tyrosine kinase inhibitors (TKIs): A game changer in cancer therapyTyrosine kinase inhibitors (TKIs) have become increasingly important in the treatment of multiple cancers. They basically work by blocking signaling pathways that drive tumor growth in cancer

Merck buys exclusive rights to develop Hengrui pharma's lp(a) inhibitor outside of china.